ST. PETERSBURG, Fla., Oct. 22 /PRNewswire-FirstCall/ -- The Advanced Wound Management Division of Smith & Nephew, Inc.,a subsidiary of Smith & Nephew Plc (LSE: SN; NYSE: SNN), announced today that clinicians will present a total of 20 clinical posters featuring its Negative Pressure Wound Therapy (NPWT) Systems and ALLEVYN™ AG, ALLEVYN AG Gentle, ACTICOAT™ and IODOSORB™
"We look forward to the presentation of such a large body of new data associated with our advanced wound management products," said Tom Dugan, North American President, Smith & Nephew Advanced Wound Management. "We are particularly excited to see the results of a large, prospective multi-center study of gauze-based NPWT on grafted and non-grafted patients. Smith & Nephew is committed to helping clinicians at every stage of wound treatment deliver the best possible care and deliver value to their healthcare institutions. We are delighted that so many clinicians are advancing new research with the aid of our comprehensive platform for the preparation, protection and progression towards healing of wounds."
The body of new data on display at the Symposium includes the following posters:
Smith & Nephew will present the comprehensive portfolio of advanced wound management products reflected in these clinical posters at Booth 111. Featured products include the RENASYS™ EZ and RENASYS™ GO Systems, and the ALLEVYN™ and ACTICOAT™ portfolios.
"The interactive booth is designed with hands-on product demonstration and training stations to enhance the customer experience," stated Ian Dawson, North American Vice President of Marketing. "Customers will be able to gain hands-on experience with the foam and gauze interfaces that are available with the RENASYS System. The versatility of the RENASYS systems allows clinicians to make their own choice to use gauze and foam wound interfaces based on the individual needs of the patient, confident that either approach will meet their clinical objectives for NPWT."
The Right Dressing for the Right Wound
The full-range ALLEVYN portfolio offers triple action technology for fluid handling capabilities, absorption, retention and transpiration. The ALLEVYN Ag line offers bactericidal levels of silver with absorption capability, while the ALLEVYN Gentle range was developed to address the needs of fragile skin. Smith & Nephew is the only company to offer a combination of antimicrobial capability and gentle adhesive technology in the ALLEVYN Ag Gentle Border Dressing. ALLEVYN Adhesive is available for high friction areas and ALLEVYN Non-Adhesive for compromised skin.
ACTICOAT is a trusted first line antimicrobial intervention to help prevent and manage life threatening infections in a range of dressing types. The ACTICOAT portfolio presentation will focus on the recently introduced ACTICOAT Flex line, which provides flexible conformability for anatomical areas such as face and hands and breakthrough stretch properties to improve patient comfort during wear.
The Symposium is being held at the Henry B. Gonzalez Convention Center in San Antonio, Texas, from October 22 to 25, 2009.
For more information about Smith & Nephew, please go to www.smith-nephew.com. Product-specific information is available at www.myrenasys.com, www.allevyn.com, www.iodosorb.com, and www.acticoat.com.
About Smith & Nephew
Smith & Nephew is a global medical technology business, specializing in Orthopeadics, including Reconstruction, Trauma and Clinical Therapies, Endoscopy and Advanced Wound Management. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopeadics companies.
Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2008 were nearly $3.8 billion.
This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding expected revenue growth and trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation, claims and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.
All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
SOURCE Smith & Nephew
Subscribe to our Free Newsletters!
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...
Sleep disorders are collectively known as ''Somnipathy.'' There are over 70 different medically ...
Unintended pregnancies are very common these days, and so one in about four pregnant women go for ...View All